Estrogen and Progesterone Market Size, Share, and Trends Analysis Report, Forecast Period 2024-2031.

The global estrogen and progesterone market is anticipated to grow at a considerable CAGR of 14.1% during the forecast period. The growing number of sex reassignment procedures performed globally is one of the major factors driving the growth of the estrogen and progesterone market. Such treatments provide functional abilities and physical appearance to the transgender with sexual characteristics they believe belong to. The increasing awareness and rising social acceptance of transgender, LGBT, and people will also give significant support to the estrogen and progesterone market during the forecast period. Additionally, supportive reimbursement policies in developed nations including the US, the UK, and Germany will also boost the number of sex reassignment procedures. Insurance companies including Aetna and Unicare provide insurance cover for such treatments.

Get Sample Copy of this Report at

https://www.omrglobal.com/request-sample/estrogen-and-progesterone-market

Moreover, the rising prevalence of uterine bleeding, amenorrhea, breast cancer, and uterus cancer are also boosting the demand for estrogen and progesterone drugs. According to the Breast Cancer Foundation Organization, in 2020, there were over 684,996 mortality from breast cancer. Survival rates of breast cancer are high if the cancer is diagnosed at an early stage, however 80% of the breast cancers are diagnosed at an advanced stage. Thus, various foundations are supporting breast cancer-specific initiatives including The Breast Cancer Research Foundation. In October 2020, the Breast Cancer Foundation announced that it is funding $40 million for breast cancer research from 2020-2021. Additionally, BCRF's 40% grants are for Metastatic breast cancer which funded 88 projects in 2020. These factors are driving the demand for estrogen and progesterone drugs globally.

full report of available

https://www.omrglobal.com/industry-reports/estrogen-and-progesterone-market

However, the consumption of estrogen and progesterone has severe long-term side effects, such as headaches, mood swings, and back pain, among others, which will hamper the growth of the estrogen and progesterone market. This report will further analyze all the primary as well as secondary factors that are directly or indirectly impacting the growth of the market.

Various non-essential surgeries and treatments including sex reassignment treatment for the gender dysphoria patients were postponed during the COVID-19 pandemic. This had drastically reduced the demand for estrogen and progesterone drugs globally. The high cost associated with sex reassignment treatment is another major restraining factor for the market. The market is expected to show a U-shaped recovery after the COVID-19 situation gets normalized.

Segmental Outlook

The global estrogen and progesterone market is segmented based on the type and distribution channel. Based on the type, the market is segmented into aglepristone, mifepristone, asoprisnil, telapristone, and ulipristal acetate. Based on the distribution channel, the market is sub-segmented into pharmacy and hospital and clinics. Among these distribution channels, the hospital segment holds the major share in the market as it is the most trusted source for drug purchases among consumers. However, the pharmacy segment is expected to grow fastest during the forecast period owing to the rising trend of OTC drugs and attractive discounts offered by these pharmacies. The above-mentioned segments can also be customized as per the requirements.

by Type (Aglepristone, Mifepristone, Asoprisnil, Telapristone, and Ulipristal Acetate) and

By Distribution Channel (Pharmacy, Hospital and Clinics)

Market Players Outlook

The major companies serving the global estrogen and progesterone market include AstraZeneca Ltd., Teva Pharmaceutical Industries Ltd., Abbott Healthcare Products B.V., Novartis International AG, Pfizer Inc., Merck Serono Ltd., and Bayer AG, among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance-

Bayer AG announced the acquisition of KanDy Therapeutics Inc. in August 2020, which aids in the expansion of Bayer's women's drug pipeline by adding KanDy's menopause drug to its portfolio.
Mankind Pharma launched the generic Dydrogesterone tablets for the treatment of infertility and pregnancy-related complications in the Indian market in December 2019. This was carried out to expand the treatment options and gain a competitive edge.
The Report Covers

Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global estrogen and progesterone market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

For More Customized Data, Request for Report Customization

https://www.omrglobal.com/report-customization/estrogen-and-progesterone-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.